Aarti Pharmalabs FY26 Annual Earnings Summary

While current tariffs exempt pharma, potential changes under Section 232 could impact API exports; management noted contracts are largely FOB but impact unclear.

Startup hiccups at Atali have impacted production plans; resolution expected by Q4 but may slip further, delaying revenue ramp-up.

API revenue declined YoY due to pricing pressure and slower customer off-take; recovery may take several quarters.

Geopolitical tensions have caused significant increases in raw material and logistics costs, impacting margins, especially in the API segment where cost pass-through is difficult.

CDMO revenue is back-end loaded and lumpy due to multi-stage manufacturing; Q1 performance may not be indicative of full-year trajectory.

GPL plant underwent shutdown for modifications; restart in July may delay contribution to profitability in FY26.

Atali greenfield plant will have higher opex initially; full utilization may take until end of FY26, pressuring near-term margins.

80% of CDMO sales come from 7-8 projects; failure of any key project could materially impact revenue.

While China's rebate withdrawal could boost pricing, locked-in contracts may limit near-term realization.

Management noted that existing orders in the API segment cannot be repriced, and future price increases depend on competitive dynamics.

CDMO revenue is lumpy due to project-based deliveries, and large customer orders require significant inventory financing without advances.

A ₹33 crore forex loss in FY26 (including on foreign currency loans) highlights exposure to currency fluctuations, with potential for further hits.